| Title: | Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C |
| Authors: | Suda, Goki Browse this author →KAKEN DB |
| Kudo, Mineo Browse this author |
| Nagasaka, Atsushi Browse this author |
| Furuya, Ken Browse this author |
| Yamamoto, Yoshiya Browse this author |
| Kobayashi, Tomoe Browse this author |
| Shinada, Keisuke Browse this author |
| Tateyama, Miki Browse this author |
| Konno, Jun Browse this author |
| Tsukuda, Yoko Browse this author |
| Yamasaki, Kazushi Browse this author |
| Kimura, Megumi Browse this author |
| Umemura, Machiko Browse this author |
| Izumi, Takaaki Browse this author |
| Tsunematsu, Seiji Browse this author |
| Sato, Fumiyuki Browse this author |
| Terashita, Katsumi Browse this author |
| Nakai, Masato Browse this author |
| Horimoto, Hiromasa Browse this author |
| Sho, Takuya Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Morikawa, Kenichi Browse this author |
| Ogawa, Koji Browse this author |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Keywords: | HCV |
| Hemodialysis |
| Daclatasvir |
| Asunaprevir |
| Issue Date: | Jul-2016 |
| Publisher: | Springer |
| Journal Title: | Journal of gastroenterology |
| Volume: | 51 |
| Issue: | 7 |
| Start Page: | 733 |
| End Page: | 740 |
| Publisher DOI: | 10.1007/s00535-016-1162-8 |
| PMID: | 26768604 |
| Abstract: | Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures. However, options of anti-HCV therapy in such patients are limited and unsatisfactory. In this study, we report effectiveness and safety of HCV-NS5A-inhibitor daclatasvir (DCV) and protease-inhibitor asunaprevir (ASV) combination therapy for hemodialysis patients with HCV infection. Methods: This study was registered at the UMIN Clinical Trials Registry as UMIN000016355. Thirty-four dialysis patients were treated with DCV/ASV combination therapy between January 2015 and November 2015. Of those, 21 patients who were followed more than 12 weeks after treatment ended were included. We evaluated the 12-week sustained virologic response (SVR12) and adverse events during treatment. Results: Of the 21 patients, four had compensated liver cirrhosis and three had resistance-associated variant of NS5A (NS5A RAVs)-Y93H at baseline. Overall, total of 95.5 % (20/21) of the patients achieved SVR12. Of note, all patients with cirrhosis or NS5A RAVs achieved SVR12. One relapser patient at 4 weeks post-treatment had NS3 D168E RAVs at baseline. A total of 20 patients (95.5 %) completed the 24-week therapy. One patient discontinued treatment at week 12 due to ALT elevations and achieved SVR12. Conclusions: DAV and ASV combination therapy for chronic hemodialysis patients with HCV infection was highly effective and well tolerated, even in elderly patients and patients with liver cirrhosis and NS5A-RAVs. |
| Rights: | The final publication is available at Springer via http://dx.doi.org/10.1007/s00535-016-1162-8 |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/66412 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
